Covovax
img

DCGI approves market authorisation for SII's Covid vaccine Covovax as heterologous booster dose

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation.

published on : 17th January 2023
img

Commercial use of SII’s Covovax as heterologous booster jab gets government nod

According to officials, the subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO), which met on Wednesday, deliberated on the issue.

published on : 13th January 2023
img

COVID-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar Poonawalla 

Covovax works very well against omicron variant,more than Covishield, says Adar Poonawalla.

published on : 9th January 2023
img

SII seeks nod to export 32.4 lakh doses of its Covid vaccine Covovax to US

The sources said it will be the first instance of any Indian manufacturer's vaccine -- Covid or non-Covid -- to be exported to the US.

published on : 30th June 2022
img

Government panel recommends emergency approval for SII's Covovax for 7-11 year olds

The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.

published on : 24th June 2022
img

SII's COVID vaccine Covovax now available for 12-17 age group at private centres

Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal.

published on : 2nd May 2022
img

Poonawalla warns against return to business-as-usual approach 

Calling for increased adoption of booster doses, Poonawalla said it is also needed because people need to travel internally and outside,  many countries have made booster doses mandatory for travel.

published on : 22nd April 2022
img

Panel seeks more data on Serum Institute's EUA application for Covovax use

The SII had last month submitted an application to the Drugs Controller General of India (DCGI) seeking emergency use authorisation (EUA) for Covovax's use among children in the age group.

published on : 12th April 2022
img

Govt panel recommends inclusion of Covovax in national Covid vaccination drive for those aged 12 and above

India's drug regulator had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12-17 age group, subject to certain conditions, on March 9.

published on : 3rd April 2022
img

India's drugs regulator gives nod to phase-3 clinical trial of Covid vaccine Covovax

CDSCO had recommended permission for conducting phase-3 clinical trial for Covovax as booster dose in adults who have been fully vaccinated with either Covaxin or Covishield least three months ago.

published on : 23rd March 2022
img

DCGI's EUA nod to SII's Covovax for 12-17 years age group

Poonawalla says younger age groups to follow shortly

published on : 9th March 2022
img

Covid: Government panel recommends permission for phase-3 trial of Covovax as booster dose in adults

The Drugs Controller General Of India (DCGI) has already approved Covovax for restricted use in emergency situations in adults on December 28.

published on : 6th March 2022
img

Covovax EUA recommended for 12-17 group

The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 last year. It is yet to be used in India’s vaccination drive.

published on : 5th March 2022
img

Government panel recommends EUA for Covid vaccine Covovax for 12-17 age group

The Drugs Controller General of India (DCGI) had approved Covovax for restricted use in emergency situation in adults on December 28.

published on : 4th March 2022